Pediatrix Medical Group, Inc. (NYSE:MD) Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lowered its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 5.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,244,950 shares of the company’s stock after selling 74,289 shares during the period. Segall Bryant & Hamill LLC owned 1.45% of Pediatrix Medical Group worth $14,429,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Rubric Capital Management LP lifted its position in shares of Pediatrix Medical Group by 797.0% during the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. lifted its position in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after acquiring an additional 455,785 shares during the last quarter. Boston Partners boosted its stake in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after purchasing an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth about $1,721,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MD shares. Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Tuesday. StockNews.com lowered shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday. Truist Financial upped their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Finally, Jefferies Financial Group increased their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Trading Down 0.8 %

Shares of Pediatrix Medical Group stock opened at $14.49 on Thursday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -4.74, a price-to-earnings-growth ratio of 2.03 and a beta of 1.55. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $16.41. The company’s 50-day simple moving average is $12.77 and its 200-day simple moving average is $9.96. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same quarter in the previous year, the firm posted $0.29 EPS. The firm’s quarterly revenue was up .9% on a year-over-year basis. As a group, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is owned by company insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.